NCT06595992 Prospective Observational Cohort Study of Moderate Aortic Valve Disease
| NCT ID | NCT06595992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Moderate Aortic Valve Stenosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2034-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-09-01 with a primary completion date of 2034-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al. Additionally, try to analyze the potential impact of device or drug therapy on the progression of the conditions.
Eligibility Criteria
Inclusion Criteria: * At least 18 years old * Be willing and able to provide informed consent to participate in the study * Patient has moderate aortic valve diseases with echocardiographically derived criteria Exclusion Criteria: * Severe aortic valve diseases with echocardiographically derived criteria or planned cardiac surgery or likely need for surgery within 6 months * Patients who have undergone elective transfemoral transcatheter aortic valve replacement * Life expectancy is less than 12 months due to non-heart disease (such as cancer, chronic liver disease, chronic kidney disease, or chronic end-stage lung disease, etc.) * Severe dementia (cannot sign research informed consent, cannot take care of themselves or complete the study visit) * Acute pulmonary oedema or cardiogenic shock * The investigator believes that the patient is not suitable to participate in the study or complete the follow-up prescribed by the protocol from other medical, social and psychological aspects * The patient is currently participating in another randomized study
Contact & Investigator
Jianan Wang, Dorctor
PRINCIPAL INVESTIGATOR
Second Affiliated Hospital of Zhejiang University, School of Medicine
Frequently Asked Questions
Who can join the NCT06595992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Moderate Aortic Valve Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06595992 currently recruiting?
Yes, NCT06595992 is actively recruiting participants. Contact the research team at liuxb@zju.edu.cn for enrollment information.
Where is the NCT06595992 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06595992 clinical trial?
NCT06595992 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Jianan Wang, Dorctor at Second Affiliated Hospital of Zhejiang University, School of Medicine. The trial plans to enroll 1,000 participants.